ARDELYX INC

Ardelyx faces a major setback after an appeals court upheld Medicare coverage limits, impacting revenue and strategy for its metabolic disorder drugs.

Ardelyx’s innovative drugs target GI transporters to treat mineral metabolism and metabolic disorders, offering new hope for kidney disease patients.

Ardelyx, Inc. innovates in biotech by targeting gastrointestinal transporters to treat mineral metabolism disorders, driving new therapies and improving patient outcomes.

Ardelyx’s IBS‑C study accepted for Digestive Disease Week 2026 poster; shares hit a 200‑day low, while analyst ratings hover around “Moderate Buy.

Ardelyx’s new partnership and promising preclinical data signal a boost for its mineral‑metabolism drugs, while disciplined capital strategy keeps investors focused on long‑term growth.

Ardelyx’s latest SEC filing reveals CMO stock‑unit details amid a dynamic biotech market, spotlighting its focus on innovative metabolic disorder therapies.

Ardelyx, Inc. develops gut‑targeted drugs for mineral‑metabolism disorders and trades on Nasdaq with a $1.46 bn market cap, offering insight into its biotech strategy and insider holdings.

Ardelyx, Inc. drives biotech innovation by targeting gastrointestinal transporters to correct mineral metabolism disorders, offering a unique therapeutic pipeline amid market volatility.

Ardelyx Inc. leads biotech with targeted GI tract drugs correcting mineral metabolism, while navigating growth challenges—discover its latest therapies and market outlook.

Ardelyx’s latest earnings reveal a biotech firm focused on GI‑centric metabolic drugs, trading at $5.73 with a $1.41B market cap and high investor confidence.